⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16338698 | 0.86 | — | — | |
| SCHEMBL18763487 | 0.82 | — | — | |
| SCHEMBL23290601 | 0.80 | — | — | |
| SCHEMBL23290774 | 0.80 | — | — | |
| SCHEMBL14831314 | 0.80 | — | — | |
| SCHEMBL18763488 | 0.78 | — | — | |
| SCHEMBL1299563 | 0.67 | — | — | |
| SCHEMBL18763434 | 0.67 | — | — | |
| SCHEMBL18763461 | 0.64 | CRBN (0.35) | — | |
| SCHEMBL18763419 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2213673-B1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD KK (JP) | 2013-06-05 | — | — | EP | claimed |
| US-8329711-B2 | Pyridone-substituted-dihydropyrazolopyrimidinone derivative | MSD K.K. (JP) | 2012-12-11 | — | — | US | claimed |
| US-20100221211-A1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD K.K. (JP) | 2010-09-02 | — | — | US | claimed |
| EP-2213673-A1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-08-04 | — | — | EP | claimed |
| EP-4398254-A2 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | Memorial Sloan Kettering Cancer Center (US) | 2024-07-10 | — | — | EP | disclosed |
| US-12023371-B2 | Terminally modified RNA | MODERNATX, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| US-11987590-B2 | Compounds that participate in cooperative binding and uses thereof | Revolution Medicines, Inc. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240123035-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | ARES CAPITAL CORPORATION, AS AGENT | 2024-04-18 | — | — | US | disclosed |
| EP-4351662-A1 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2024-04-17 | — | — | EP | disclosed |
| EP-2991655-B1 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240042000-A1 | CARBOHYDRATE STRUCTURES AND USES THEREOF | 6452728 CANADA CORP (CA) | 2024-02-08 | — | — | US | disclosed |
| US-8329711-B2 | Pyridone-substituted-dihydropyrazolopyrimidinone derivative | MSD K.K. (JP) | 2012-12-11 | — | — | US | disclosed |
| EP-2376493-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE | MSD K.K. (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20110243891-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD K.K. | 2011-10-06 | — | — | US | disclosed |
| US-20100221211-A1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD K.K. (JP) | 2010-09-02 | — | — | US | disclosed |
| EP-2213673-A1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-08-04 | — | — | EP | disclosed |
| WO-2010067886-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-06-17 | — | — | WO | disclosed |
| US-5284855-A | Broad-spectrum antibiotics; gramnegative and -positive bacteria, esp. Enterobacter | BAYER AKTIENGESELLSCHAFT (DE) | 1994-02-08 | — | — | US | disclosed |
| US-5202337-A | Antibacterial agent, feed additive | BAYER AKTIENGESELLSCHAFT (DE) | 1993-04-13 | — | — | US | disclosed |